Carolina AlarcoFounder & Principal, Bio Strategy Advisors, and Co-Founder & Co-Chair, Latinos in Bio at Bio Strategy AdvisorsAdvisor, Speaker
Profile
Carolina Alarco is a senior biotech executive with more than 25 years of experience in the biopharmaceutical industry in Massachusetts. She is the Founder and Principal at Bio Strategy Advisors, a strategic business consulting firm specializing in start-up formation, corporate strategy, investor-readiness, strategic partnerships and geographical expansion. She is an Advisory Board Member for Cell and Gene Therapy at Informa Connect Life Sciences. Carolina is also a Strategic Consultant at Interlink Markets, a boutique Investment Bank. Previously, spent 15 years at Genzyme where she was a VP, until the acquisition by Sanofi in 2011. She was then a President at Aegerion Pharmaceuticals and at Novelion Therapeutics, until their respective exits. Carolina is an Angel Investor at Walnut Ventures, TBD Angels, The Longevity Investors Network and AccelHUB Ventures. Carolina serves on the Board of 3 private biotech companies: Syte.bio, NED Biosystems and Dione Antibiotics, as well as, on the Board of Advisors of Eastern Bank, a publicly traded bank in Boston. Carolina also serves in several non-profit Boards: MassBio, the Massachusetts Biotechnology Council; Latinos in Bio, of which she is co-Founder and Co-Chair; and the Mass General Hospital Board of Trustees (MGPO). Carolina has been recently featured in the Boston Business Journal’s Women Who Lead in the Life Sciences (October 2023), in The Boston Globe as one of Amplify LatinX 100 change-making leaders from across the commonwealth of Massachusetts (September 2023), in Boston Magazine as one of the one 150 Most Influential Bostonians (April 2023); in The Boston Globe as one of the leading faces of Biotech in Boston (March 2021); and in the Boston Business Journal as one of the Power 50 “Movement Makers” (November 2021).
Agenda Sessions
Building Winning Teams: Essential Ingredients for Successful Advanced Therapy Collaborations
, 5:00pmView SessionLatinos in Bio Panel - Missed Opportunities: The Cost of Ignoring Diversity in Biotech
, 4:35pmView Session